C2 and atherosclerosis: Since the C2 mAb was originally characterized as an antibody that recognizes injury-exposed phospholipids normally recognized by natural circulating IgM, and phospholipids make up the outer shell of lipoproteins, we examined the effect of C2scFv-Crry on lipoprotein uptake, which is a critical event in the progression of atherosclerosis.